120 related articles for article (PubMed ID: 22339435)
41. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
42. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Levine RL; Wadleigh M; Cools J; Ebert BL; Wernig G; Huntly BJ; Boggon TJ; Wlodarska I; Clark JJ; Moore S; Adelsperger J; Koo S; Lee JC; Gabriel S; Mercher T; D'Andrea A; Fröhling S; Döhner K; Marynen P; Vandenberghe P; Mesa RA; Tefferi A; Griffin JD; Eck MJ; Sellers WR; Meyerson M; Golub TR; Lee SJ; Gilliland DG
Cancer Cell; 2005 Apr; 7(4):387-97. PubMed ID: 15837627
[TBL] [Abstract][Full Text] [Related]
43. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
44. Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia.
Alvarez-Larrán A; Senín A; Fernández-Rodríguez C; Pereira A; Arellano-Rodrigo E; Gómez M; Ferrer-Marin F; Martínez-López J; Camacho L; Colomer D; Angona A; Navarro B; Cervantes F; Besses C; Bellosillo B; Hernández-Boluda JC
Br J Haematol; 2017 Sep; 178(5):764-771. PubMed ID: 28542718
[TBL] [Abstract][Full Text] [Related]
45. The glucocorticoid receptor A3669G SNP is not associated with polycythemia vera, essential thrombocythemia or primary myelofibrosis.
Costache RM; Bănescu C; Popp RA; Pop IV; Trifa AP
Leuk Lymphoma; 2016; 57(1):209-11. PubMed ID: 25926062
[No Abstract] [Full Text] [Related]
46. Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs).
Reilly JT
Leukemia; 2008 Oct; 22(10):1818-27. PubMed ID: 18754027
[TBL] [Abstract][Full Text] [Related]
47. Another piece of the myeloproliferative neoplasms puzzle.
Levine RL
N Engl J Med; 2013 Dec; 369(25):2451-2. PubMed ID: 24325357
[No Abstract] [Full Text] [Related]
48. Low expression of the putative tumour suppressor gene gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia.
Boultwood J; Pellagatti A; Watkins F; Campbell LJ; Esoof N; Cross NC; Eagleton H; Littlewood TJ; Fidler C; Wainscoat JS
Br J Haematol; 2004 Aug; 126(4):508-11. PubMed ID: 15287943
[TBL] [Abstract][Full Text] [Related]
49. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
[TBL] [Abstract][Full Text] [Related]
50. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
51. Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis.
Kandarpa M; Wu YM; Robinson D; Burke PW; Chinnaiyan AM; Talpaz M
Am J Hematol; 2017 Jun; 92(6):555-561. PubMed ID: 28335073
[TBL] [Abstract][Full Text] [Related]
52. JAK inhibitor in CALR-mutant myelofibrosis.
Passamonti F; Caramazza D; Maffioli M
N Engl J Med; 2014 Mar; 370(12):1168-9. PubMed ID: 24645956
[No Abstract] [Full Text] [Related]
53. JAK inhibitor in CALR-mutant myelofibrosis.
Cazzola M; Kralovics R
N Engl J Med; 2014 Mar; 370(12):1169. PubMed ID: 24645955
[No Abstract] [Full Text] [Related]
54. [Research progress on molecular pathogenesis of myeloproliferative neoplasms].
Liu L; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):239-43. PubMed ID: 21362261
[TBL] [Abstract][Full Text] [Related]
55. [Diagnostic molecular pathology of lymphatic and myeloid neoplasms].
Klapper W; Kreipe H
Pathologe; 2015 Mar; 36(2):164-70. PubMed ID: 25809654
[TBL] [Abstract][Full Text] [Related]
56. Alterations of NFIA in chronic malignant myeloid diseases.
Bernard F; Gelsi-Boyer V; Murati A; Giraudier S; Trouplin V; Adélaïde J; Rey J; Olschwang S; Vainchenker W; Chaffanet M; Vey N; Mozziconacci MJ; Birnbaum D
Leukemia; 2009 Mar; 23(3):583-5. PubMed ID: 18754024
[No Abstract] [Full Text] [Related]
57. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
Ganly P; Hanrahan V; Baker B; Romeril K
Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
[TBL] [Abstract][Full Text] [Related]
58. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.
Cambier N; Renneville A; Cazaentre T; Soenen V; Cossement C; Giraudier S; Grardel N; Laï JL; Rose C; Preudhomme C
Leukemia; 2008 Jul; 22(7):1454-5. PubMed ID: 18288134
[No Abstract] [Full Text] [Related]
59. Myelosclerosis: a study of a condition also known as myelofibrosis, aleuchaemic myelosis, agnogenic myeloid metaplasia, and other titles.
ROBSON HN
Australas Ann Med; 1953 Nov; 2(2):170-8. PubMed ID: 13115298
[No Abstract] [Full Text] [Related]
60. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
